ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib

by Zacks Equity Research Published on February 07,2017

ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).

• PFE Quick QuotePFEPositive Net Change
• LLY Quick QuoteLLYNegative Net Change
• ENZ Quick QuoteENZNegative Net Change
• ARIA Quick QuoteARIAPositive Net Change

Varian Medical (VAR) Misses on Q1 Earnings and Revenues

by Zacks Equity Research Published on January 26,2017

Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 75 cents per share in the first quarter of fiscal 2017.

• VAR Quick QuoteVARPositive Net Change
• HOLX Quick QuoteHOLXNegative Net Change
• ARIA Quick QuoteARIAPositive Net Change
• GKOS Quick QuoteGKOSPositive Net Change

McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal

by Zacks Equity Research Published on January 26,2017

McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.

• HOLX Quick QuoteHOLXNegative Net Change
• ARIA Quick QuoteARIAPositive Net Change
• MCK Quick QuoteMCKNegative Net Change
• GKOS Quick QuoteGKOSPositive Net Change

Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance

by Zacks Equity Research Published on January 25,2017

Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate by 2 cents.

• HOLX Quick QuoteHOLXNegative Net Change
• SYK Quick QuoteSYKPositive Net Change
• ARIA Quick QuoteARIAPositive Net Change
• GKOS Quick QuoteGKOSPositive Net Change

Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues

by Zacks Equity Research Published on January 25,2017

Intuitive Surgical Inc. (ISRG) posted adjusted earnings of $5.30 per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate by four cents.

• GS Quick QuoteGSNegative Net Change
• ISRG Quick QuoteISRGNegative Net Change
• HOLX Quick QuoteHOLXNegative Net Change
• ARIA Quick QuoteARIAPositive Net Change

5 Best Performing Healthcare Mutual Funds of 2016

by Zacks Equity Research Published on January 23,2017

Investors rely on the healthcare firms to safeguard their investments as demand for its services does not vary much with market conditions

• JNJ Quick QuoteJNJPositive Net Change
• ALIOF Quick QuoteALIOFNo Net Change
• ARIA Quick QuoteARIAPositive Net Change
• TKPYY Quick QuoteTKPYYNo Net Change
• FSPHX Quick QuoteFSPHXNegative Net Change

Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA

by Zacks Equity Research Published on January 20,2017

Shire plc (SHPG) announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application (NDA) for pipeline candidate, SHP465.

• ANIK Quick QuoteANIKNegative Net Change
• ARIA Quick QuoteARIAPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change
• ADHD Quick QuoteADHDPositive Net Change

Allergan (AGN) Rhofade Cream for Rosacea Approved in U.S.

by Zacks Equity Research Published on January 20,2017

Allergan plc (AGN) announced that the FDA has approved Rhofade (oxymetazoline hydrochloride) cream for topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

• AGN Quick QuoteAGNPositive Net Change
• ENZ Quick QuoteENZNegative Net Change
• SCMP Quick QuoteSCMPPositive Net Change
• ARIA Quick QuoteARIAPositive Net Change

Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication

by Zacks Equity Research Published on January 20,2017

AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

• JNJ Quick QuoteJNJPositive Net Change
• ENZ Quick QuoteENZNegative Net Change
• ARIA Quick QuoteARIAPositive Net Change
• ABBV Quick QuoteABBVNegative Net Change

Can The Uptrend Continue for ARIAD Pharmaceuticals (ARIA)?

by Zacks Equity Research Published on January 20,2017

Investors certainly have to be happy with ARIAD Pharmaceuticals, Inc. (ARIA) and its short term performance

• ARIA Quick QuoteARIAPositive Net Change

Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

by Zacks Equity Research Published on January 18,2017

Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.

• SNY Quick QuoteSNYPositive Net Change
• ENZ Quick QuoteENZNegative Net Change
• ANIK Quick QuoteANIKNegative Net Change
• ARIA Quick QuoteARIAPositive Net Change

Jazz Begins Phase III Study for Label Expansion of Defitelio

by Zacks Equity Research Published on January 18,2017

Jazz Pharmaceuticals Public Limited Company (JAZZ) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease.

• ENZ Quick QuoteENZNegative Net Change
• ANIK Quick QuoteANIKNegative Net Change
• ARIA Quick QuoteARIAPositive Net Change
• JAZZ Quick QuoteJAZZPositive Net Change

Becton, Dickinson Commercially Launches Precise WTA Kits

by Zacks Equity Research Published on January 18,2017

Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.

• ARIA Quick QuoteARIAPositive Net Change
• BDX Quick QuoteBDXNegative Net Change
• PEN Quick QuotePENNegative Net Change
• GKOS Quick QuoteGKOSPositive Net Change

Baxter (BAX): Sluggish Macro Environment Mars Prospects

by Zacks Equity Research Published on January 18,2017

On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

• BAX Quick QuoteBAXPositive Net Change
• ARIA Quick QuoteARIAPositive Net Change
• PEN Quick QuotePENNegative Net Change
• GKOS Quick QuoteGKOSPositive Net Change

ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher

by Zacks Equity Research Published on January 13,2017

ArQule, Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 7% on the day.

• ARIA Quick QuoteARIAPositive Net Change
• ARQL Quick QuoteARQLPositive Net Change

ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

by Zacks Equity Research Published on January 13,2017

On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).

• BMY Quick QuoteBMYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• NVS Quick QuoteNVSPositive Net Change
• ARIA Quick QuoteARIAPositive Net Change

ARIAD Pharma Stock Gains on Acquisition Deal with Takeda

by Zacks Equity Research Published on January 10,2017

ARIAD Pharmaceuticals, Inc.'s (ARIA) shares surged 72.8% after the company announced a definitive agreement to be acquired by Japan-based Takeda Pharmaceutical Company Limited (TKPYY) for approximately $5.2 billion.

• ENZ Quick QuoteENZNegative Net Change
• KITE Quick QuoteKITENegative Net Change
• ARIA Quick QuoteARIAPositive Net Change
• TKPYY Quick QuoteTKPYYNo Net Change

ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong

by Zacks Equity Research Published on December 30,2016

Shares of ARIAD Pharma surged 98.4% year to date and outperformed the Zacks classified Medical-Drugs industry that declined 25.4%.

• BMY Quick QuoteBMYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• NVS Quick QuoteNVSPositive Net Change
• ARIA Quick QuoteARIAPositive Net Change

ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

by Zacks Equity Research Published on November 30,2016

ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.

• BMY Quick QuoteBMYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• NVS Quick QuoteNVSPositive Net Change
• ARIA Quick QuoteARIAPositive Net Change

by Zacks Equity Research Published on November 18,2016

• EDU Quick QuoteEDUNegative Net Change
• BJRI Quick QuoteBJRINegative Net Change
• ARIA Quick QuoteARIAPositive Net Change
• EXEL Quick QuoteEXELNegative Net Change

What's at Stake for Wall Street This Election?

by Mark Vickery Published on November 07,2016

Not just the presidential race, but which party controls the Senate will have "yuge" implications on future U.S. policy, economic and otherwise.

• SNI Quick QuoteSNINegative Net Change
• SYY Quick QuoteSYYNegative Net Change
• BRK.B Quick QuoteBRK.BPositive Net Change
• ARIA Quick QuoteARIAPositive Net Change

Fundamentals Remain Strong in the Pharma Sector

by Arpita Dutt Published on November 04,2016

We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.

• ARIA Quick QuoteARIAPositive Net Change
• BIIB Quick QuoteBIIBNegative Net Change
• AMGN Quick QuoteAMGNNegative Net Change
• CELG Quick QuoteCELGPositive Net Change

Top Ranked Momentum Stocks to Buy for October 31st

by Tirthankar Chakraborty Published on October 31,2016

Here are four stocks with buy ranks and strong momentum characteristics for investors to consider today, October 31st:

• ACIA Quick QuoteACIANegative Net Change
• ALSN Quick QuoteALSNNegative Net Change
• ARIA Quick QuoteARIAPositive Net Change
• ACGL Quick QuoteACGLPositive Net Change

Explosive Stocks Under $10

by Kevin Matras Published on March 22,2016

Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include PETX, AKS, ARIA, LSG and PVG.

• PVG Quick QuotePVGPositive Net Change
• ARIA Quick QuoteARIAPositive Net Change
• AKS Quick QuoteAKSPositive Net Change
• PETX Quick QuotePETXPositive Net Change

3 Biotechs Looking Good this Earnings Season

by Zacks Equity Research Published on January 30,2015

A number of biotech companies are seeing improvements in their financial results.

• ARIA Quick QuoteARIAPositive Net Change
• BCRX Quick QuoteBCRXPositive Net Change
• PCYC Quick QuotePCYCPositive Net Change